Three firms lifted price targets on URGN after a strong earnings print on August 5. That catalyst is still reverberating across the lending market and options desk.
Guggenheim, HC Wainwright, and TD Cowen all raised targets on August 5–6. HC Wainwright went furthest — lifting its target from $45 to $75. TD Cowen moved from $50 to $60. Guggenheim went from $42 to $58. All three maintained Buy ratings. The consensus target now stands at $58.25, against a last close of $48.22. That implies roughly 21% upside to the mean target.
The earnings move itself was +14.2% on the day. The five-day follow-through reached +22.7%. UroGen's bull case centers on its Jelmyto and Zusduri launches plus a Teva settlement that protects near-term revenues. Bears point to rising launch costs for UGN-103 and potential generic competition starting in the early 2030s.
Short interest has dropped sharply. It stood near 13.7% of free float in early July. By August 14 it had fallen to 9.7% — a 33% decline over the past month and a 21% drop in just the past week. More than 1.6 million short shares have been returned since August 7.
The borrow market remains loose. Availability sits at 894% — roughly nine borrowable shares for every one already lent out. That gives remaining shorts ample room to stay in position. Despite the covering, cost to borrow jumped 165% week-on-week to 0.45% annually — still an absolute low, but the directional spike is worth watching as remaining shorts reassess.
The put-call ratio dropped to 0.46 on August 14. That sits 2.2 standard deviations below its 20-day average of 0.48. It is the lowest PCR reading since mid-July. Call buying has accelerated through the month-to-date rally of 23%.
The 52-week PCR range runs from 0.18 to 0.89. At 0.46, options positioning is tilted toward calls but not yet at an extreme — the low end of the annual range is well below current levels.
The 30-day EPS momentum factor score sits at 100 — the highest possible reading. Twelve-month forward EPS estimates are also trending higher, with a score of 80. The ORTEX short score has dipped from 61 in early August to 55.9, reflecting the short covering and easing squeeze pressure.
Institutional flow has been broadly additive. BlackRock added 355,894 shares as of July 31. Toronto-Dominion added 753,243 shares as of June 30. Kynam Capital entered with a new 2.25 million-share position.
See the live data behind this article on ORTEX.
Open URGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
